🚨🧬 Registrations for the IV Bootcamp are now open! Limited to 30 spots—first come, first served. Acces the link in this thread.

🧬💖You are still on time to send an abstract or register with an early fee to the ESC CardioGenomics conference in Lisbon! Share you science with top researchers from across Europe 🇪🇺

🗓️Abstracts deadline: 16 September 25
🗓️Early fee registration: 13 October 25

See you there!

🗓️ 🧬 I am happy to announce that our next Bootcamp of Genetics for cardiologists will be an special edition in English. It will take place on May 8th 2026 in Barcelona just the day before ESC HFA congress so you can make the most of your trip!

🗓️ El próximo 2 de octubre hablaremos sobre genética de la amiloidosis hereditaria en un taller presencial en el Hospital Clínic de Barcelona

Las inscripciones son gratuitas hasta completar aforo. Podéis apuntaros en la dirección de correo que aparece en el cartel

Nos vemos!

Muchas gracias a @secardiologia.bsky.social por la invitación a participar en la XI reunión de CF. Tremenda organización y nivel de ponencias! Nos vemos el año que viene en Girona!!

I would like to thank all the collaborators in this project and the Spanish section of ICC ( @secardiologia.bsky.social ) for providing funding to develop it through the Dr. William J. McKenna research grant.

This study represents the largest cohort of patients with Val142Ile ATTRv with European ancestry provinding deeper knowledge about this entity

A query to national biobanks revealed a general population frequency ranging from 0.0 to 0.12% in line with previous reports from southern European populations, suggesting that ATTRv Val142Ile might be more relevant that previously expected in southern European countries.

Tafamidis was initiated in 38 patients during follow-up (73.7% 20 mg & 26.3% 61 mg). After 1 year of treatment, 14 patients (38.9%) met the combined endpoint, with 12 cases attributed to disease progression (NTProBNP or diuretic increase) and 2 cases to cardiovascular death.

🚀A step increase in new diagnosis was described in recent years probably coupled with an increased disease of ATTR-CM among cardiologist.

📝 Excited to share our latest article on hereditary transthyretin amyloidosis (ATTRv) caused by the Val142Ile variant in Spain Here's a summary thread by the authors: @revespcardiol.bsky.social